Automated manufacturing of clinical-grade BDCA2 CAR NK cells in a closed system for the treatment of blastic plasmacytoid dendritic cell neoplasm - PubMed
6 hours ago
- #automated manufacturing
- #BPDCN
- #CAR NK cells
- Automated manufacturing of clinical-grade BDCA2 CAR NK cells in a closed system for treating blastic plasmacytoid dendritic cell neoplasm (BPDCN).
- Utilizes the CliniMACS Prodigy® platform for a cGMP-compliant Natural Killer Cell Transduction (NKCT) process.
- Closed system integrates cell separation, activation, transduction, expansion, and harvest to reduce contamination risks.
- High transduction efficiency achieved using baboon envelope pseudotyped lentiviral vectors (BaEV-LV) and Vectofusin®-1.
- Produced CAR NK cells show high viability, purity, and potent antitumor activity in vitro and in vivo.
- Enables both centralized and decentralized CAR NK manufacturing for efficient clinical translation.